Top Markets
Coin of the day
Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR
Rank in Stocks #36561
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Share Price
$1.73
Last synced: 2025-06-17
Market Cap
$2.55M
Change (1 day)
-0.29%
Change (1 year)
0.00%
Country
US
Trade Eiger BioPharmaceuticals, Inc. (EIGR)

Category

Stock price history for Eiger BioPharmaceuticals, Inc. (EIGR)
Highest end of day price: $1.73 on 2025-06-01

Lowest end of day price: $3.75K on 2014-01-01
Stock price history of Eiger BioPharmaceuticals, Inc. from 2014 to 2026
Annual Stock Price Performance
Year Performance
2025 -31.11%
2024 -68.15%
2023 -86.27%
2022 -65.86%
2021 -43.34%
2020 -27.82%
2019 28.55%
2018 -15.78%
2017 8.44%
2016 -45.90%
2015 -91.44%
2014 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE